NASDAQ
25.13USD
+1.14 (+4.75%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.7B
P/E
—
EPS
—
Beta
0.56
52W range
12.59-47.65
Day range
24.26–25.74
Open
24.26
Prev close
23.99
Volume
1.6M
Avg volume
1.5M
Dividend
0.00
IPO
2023-02-10
https://www.globenewswire.com/news-release/2026/06/14/3311447/0/en/Mineralys-Therapeutics-Presents-Late-Breaking-Data-on-Lorundrostat-and-Heart-Failure-Risk-Biomarkers-at-The-Endocrine-Society-Annual-Meeting-ENDO-2026.html · 6/14/2026+0.80
https://seekingalpha.com/article/4914090-mineralys-therapeutics-inc-mlys-presents-at-goldman-sachs-47th-annual-global-healthcare · 6/11/2026+0.20
https://www.globenewswire.com/news-release/2026/05/30/3303889/0/en/Mineralys-Therapeutics-Presents-New-Data-from-the-Phase-3-Launch-HTN-Trial-of-Lorundrostat-in-Participants-with-Hypertension-and-Chronic-Kidney-Disease-at-European-Meeting-on-Hyper.html · 5/30/2026+1.00
https://www.defenseworld.net/2026/02/07/mineralys-therapeutics-sees-unusually-large-options-volume-nasdaqmlys.html · 2/7/2026
https://www.defenseworld.net/2026/01/18/insider-selling-mineralys-therapeutics-nasdaqmlys-insider-sells-252469-75-in-stock.html · 1/18/2026-0.20
https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2808693 · 12/24/2025+1.00
https://www.defenseworld.net/2025/11/16/insider-selling-mineralys-therapeutics-nasdaqmlys-cfo-sells-5364237-12-in-stock.html · 11/16/2025-0.20
https://www.globenewswire.com/news-release/2025/11/10/3185033/0/en/Mineralys-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html · 11/10/2025+0.80
https://www.fool.com/investing/2025/09/21/2-healthcare-stocks-up-over-100-in-a-month-can-the/ · 9/21/2025+0.80
https://www.globenewswire.com/news-release/2025/09/05/3145274/0/en/Mineralys-Therapeutics-Presents-Subgroup-Analyses-of-Phase-3-Launch-HTN-Trial-Demonstrating-Efficacy-and-Safety-of-Lorundrostat-in-Hypertension-Participants-with-High-Unmet-Medical.html · 9/5/2025+1.00
https://www.investors.com/news/technology/astrazeneca-hypertension-blood-pressure-baxdrostat-mineralys-therapeutics/ · 8/30/2025+1.00
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
